IGC Pharma is a biopharmaceutical company developing therapies for Alzheimer's disease and related neurodegenerative conditions, with its lead program IGC-AD1 targeting agitation in Alzheimer's patients through a combination of cannabinoid and anti-inflammatory mechanisms. The company operates a pipeline of investigational candidates at various development stages, utilizes artificial intelligence to optimize clinical trial design and develop early disease detection tools, and holds intellectual property rights to its investigational compounds through patents and licensing agreements. IGC generates revenue through pharmaceutical development and commercialization, partnering and licensing agreements, branded wellness products, and operates an internal contract research organization to manage clinical trials efficiently.